CTRI/2018/12/016818尚未招募2 期
Randomized Control Study on Devadarvyadighanavati,Vaitaran Basti with and without Churnapottali Svedan Specifically on Disability Index Score in Amavata w.s.r.t. Rheumatoid Arthritis
Self Vaishali Krishnaji Gajbhiye0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients having signs and symptoms of Amavata mentioned in Ayurvedic texts.
- •2. Patient willing and able to participate in the study
- •3. Patients of either sex aged between 20-60 years.
- •4. Patients who have not participated in any research projects since last 6 months.
- •5. Patients of Aamvata having Sama Avastha will only be included in study.
- •6. Patients of Rheumatoid Arthritis having controlled hypertension and diabetes mellitus may also be included.
- •7. All patients fulfilling a score of 6/10 is needed for classification of patient as having definite Rheumatoid Arthritis which is American
- •criteria of rheumatoid arthritis (2010).
排除标准
- •1. Patients who are not willing for trial.
- •2. Patients with poorly controlled Hypertension (B.P. > 160/100 mm Hg).
- •3. Patients with the evidence of malignancy.
- •4. Pregnant or lactating ladies
- •5. Patient with chronicity more than >3 years.
- •6. Patients of Aamvata having Niraam- Avastha.
- •7. Patients on prolonged medication ( > 6 weeks) with corticosteroids, or any other drugs
- •that may have an influence on the outcome of the study.
- •8. Patients who are currently participating in any other clinical trials (since last 6 months).
- •9. Any other conditions which the researcher thinks may jeopardize the study.
- •10. Patients with poorly controlled Diabetes Mellitus (HBA1C 6.5 to 10 mmol/dl)
- •11. Patients having gouty arthritis, syphilitic arthritis, psoriatic arthritis, rheumatic arthritis,
- •tubercular arthritis, gonococcal arthritis etc.
- •12. Patient with contracture and having deformity in the joints.
- •13. Patients having gross disability in performing daily normal routine i.e. bed ridden patients or confined to a wheelchair or have to take help to perform daily routine activity.
研究者
相似试验
已完成
3 期
The Effectiveness, Safety and Tolerability of Actovex® Compared to Avonex® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)Comparative interventional IFN.ß-1a treatment in Relapsing Remitting Multiple Sclerosis (RRMS).Multiple SclerosisIRCT2013020812398N1Actover Pharmaceutical company138
已完成
3 期
The Effectiveness, Safety and Tolerability of Actorif® Compared to Rebif® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)IRCT2013030512398N3Biosun Pharmed Company144
已完成
3 期
The Effectiveness, Safety and Tolerability of Actoferon® Compared to Betaferon® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)Comparative interventional IFN.ß-1b treatment in Relapsing Remitting Multiple Sclerosis (RRMS).Multiple SclerosisIRCT2013030512398N2Actover Pharmaceutical company140
尚未招募
Unknown
COMPARISON OF THE EFFECTIVENESS OF CENTCHROMAN AND NORETHISTERONE IN THE TREATMENT OF HEAVY MENSTRUAL BLEEDINGCTRI/2024/07/069801ANGANA DAS
进行中(未招募)
1 期
A study evaluating the effect of EVARREST® Fibrin Sealant Patch as as an adjunct to haemostasis in controlling mild to moderate bleeding during open surgery in paediatric patientsEUCTR2013-003557-24-GBEthicon Inc40
